ZMC-001
CD19-positive B-cell malignancies
Phase 2Active
Key Facts
About Zhongmou Therapeutics
Clinical-stage biotech developing next-generation engineered T cell therapies for hematological cancers and solid tumors.
View full company profileCD19-positive B-cell malignancies
Clinical-stage biotech developing next-generation engineered T cell therapies for hematological cancers and solid tumors.
View full company profile